In conclusion, Notch3 inhibition might protect podocytes and decrease the PEC activation, suggesting a novel therapeutic strategy for FSGS and rapidly progressive glomerulonephritis (RPGN). The gene discussed is NOTCH3; the disease is rapidly progressive glomerulonephritis.